APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Duchenne Muscular Dystrophy (DMD)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Outlook and Growth Opportunities 2026

Report ID 17398628042 January 2026197 pages

Choose your research edition.

Industry ResearchDrugs for Duchenne Muscular Dystrophy (DMD) Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drugs for Duchenne Muscular Dystrophy (DMD) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Duchenne Muscular Dystrophy (DMD) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Duchenne Muscular Dystrophy (DMD) market include Bristol-Myers Squibb, Italfarmaco, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, WaVe life Science and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drugs for Duchenne Muscular Dystrophy (DMD) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Duchenne Muscular Dystrophy (DMD) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Duchenne Muscular Dystrophy (DMD) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Duchenne Muscular Dystrophy (DMD) market.

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Company

Bristol-Myers Squibb

Italfarmaco

PTC Therapeutics

Santhera Pharmaceuticals

Sarepta Therapeutics

WaVe life Science

Pfizer

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type

Eteplirsen

Deflazacort

Ataluren

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application

Home Care

Hospitals

Clinics

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Drugs for Duchenne Muscular Dystrophy (DMD) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Duchenne Muscular Dystrophy (DMD) key companies, revenue, market share, and recent developments.

3. To split the Drugs for Duchenne Muscular Dystrophy (DMD) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Duchenne Muscular Dystrophy (DMD) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Duchenne Muscular Dystrophy (DMD) significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Duchenne Muscular Dystrophy (DMD) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Duchenne Muscular Dystrophy (DMD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Duchenne Muscular Dystrophy (DMD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Duchenne Muscular Dystrophy (DMD) industry.

Chapter 3: Detailed analysis of Drugs for Duchenne Muscular Dystrophy (DMD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Duchenne Muscular Dystrophy (DMD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Duchenne Muscular Dystrophy (DMD) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends Table 2. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers Table 3. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges Table 4. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Company (2021-2026) Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company, Product Type & Application Table 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Eteplirsen Table 15. Significant Companies of Deflazacort Table 16. Significant Companies of Ataluren Table 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type (2021-2026) Table 21. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Home Care Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Clinics Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application (2021-2026) Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application (2027-2032) Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Region (2021-2026) Table 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Region (2027-2032) Table 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Market Share by Country (2021-2026) Table 38. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Market Share by Country (2027-2032) Table 40. Bristol-Myers Squibb Company Information Table 41. Bristol-Myers Squibb Business Overview Table 42. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 44. Bristol-Myers Squibb Recent Development Table 45. Italfarmaco Company Information Table 46. Italfarmaco Business Overview Table 47. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 49. Italfarmaco Recent Development Table 50. PTC Therapeutics Company Information Table 51. PTC Therapeutics Business Overview Table 52. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 54. PTC Therapeutics Recent Development Table 55. Santhera Pharmaceuticals Company Information Table 56. Santhera Pharmaceuticals Business Overview Table 57. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 59. Santhera Pharmaceuticals Recent Development Table 60. Sarepta Therapeutics Company Information Table 61. Sarepta Therapeutics Business Overview Table 62. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 64. Sarepta Therapeutics Recent Development Table 65. WaVe life Science Company Information Table 66. WaVe life Science Business Overview Table 67. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 69. WaVe life Science Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 74. Pfizer Recent Development Table 75. Research Programs/Design for This Report Table 76. Authors List of This Report Table 77. Secondary Sources Table 78. Primary Sources List of Figures Figure 1. Drugs for Duchenne Muscular Dystrophy (DMD) Product Image Figure 2. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Eteplirsen Image Figure 8. Deflazacort Image Figure 9. Ataluren Image Figure 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type (2021-2032) Figure 13. Home Care Image Figure 14. Hospitals Image Figure 15. Clinics Image Figure 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application (2021-2032) Figure 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032) & (US$ Million) Figure 22. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032) & (US$ Million) Figure 28. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Eteplirsen
  • Deflazacort
  • Ataluren
Applications
  • Home Care
  • Hospitals
  • Clinics
Companies covered
  • Bristol-Myers Squibb
  • Italfarmaco
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics
  • WaVe life Science
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Dynamics
  1. 2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends
  2. 2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers
  3. 2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges
  4. 2.4 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints
3 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Company
  1. 3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Product Type and Application
  6. 3.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Duchenne Muscular Dystrophy (DMD) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Type
  1. 4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Type Introduction
  2. 4.1.1 Eteplirsen
  3. 4.1.2 Deflazacort
  4. 4.1.3 Ataluren
  5. 4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Type
  6. 4.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type (2021-2032)
5 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Application
  1. 5.1 Drugs for Duchenne Muscular Dystrophy (DMD) Application Introduction
  2. 5.1.1 Home Care
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Application
  6. 5.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application (2021-2032)
6 Drugs for Duchenne Muscular Dystrophy (DMD) Regional Value Analysis
  1. 6.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Country, 2025 VS 2032
7 Drugs for Duchenne Muscular Dystrophy (DMD) Country-level Value Analysis
  1. 7.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Italfarmaco
  8. 8.2.1 Italfarmaco Company Information
  9. 8.2.2 Italfarmaco Business Overview
  10. 8.2.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  12. 8.2.5 Italfarmaco Recent Developments
  13. 8.3 PTC Therapeutics
  14. 8.3.1 PTC Therapeutics Company Information
  15. 8.3.2 PTC Therapeutics Business Overview
  16. 8.3.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  18. 8.3.5 PTC Therapeutics Recent Developments
  19. 8.4 Santhera Pharmaceuticals
  20. 8.4.1 Santhera Pharmaceuticals Company Information
  21. 8.4.2 Santhera Pharmaceuticals Business Overview
  22. 8.4.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  24. 8.4.5 Santhera Pharmaceuticals Recent Developments
  25. 8.5 Sarepta Therapeutics
  26. 8.5.1 Sarepta Therapeutics Company Information
  27. 8.5.2 Sarepta Therapeutics Business Overview
  28. 8.5.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  30. 8.5.5 Sarepta Therapeutics Recent Developments
  31. 8.6 WaVe life Science
  32. 8.6.1 WaVe life Science Company Information
  33. 8.6.2 WaVe life Science Business Overview
  34. 8.6.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  36. 8.6.5 WaVe life Science Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst